Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Osteoporosis

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 24 articles:
HTML format



Single Articles


    November 2020
  1. BLACK DM, Eastell R, Adams AL
    Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. Reply.
    N Engl J Med. 2020;383:2189-2190.
    PubMed    


  2. GARTON M
    Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
    N Engl J Med. 2020;383:2189.
    PubMed    


  3. OTT SM, Heckbert SR
    Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
    N Engl J Med. 2020;383:2188-2189.
    PubMed    


  4. UEDA M, Kami M
    Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
    N Engl J Med. 2020;383:2188.
    PubMed    


    August 2020
  5. BLACK DM, Geiger EJ, Eastell R, Vittinghoff E, et al
    Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
    N Engl J Med. 2020;383:743-753.
    PubMed     Abstract available


    April 2019
  6. HUMPHREY MB, Buckley L
    Glucocorticoid-Induced Osteoporosis. Reply.
    N Engl J Med. 2019;380:1379.
    PubMed    


  7. SOSA M, Gomez de Tejada MJ
    Glucocorticoid-Induced Osteoporosis.
    N Engl J Med. 2019;380:1378-1379.
    PubMed    


    December 2018
  8. BUCKLEY L, Humphrey MB
    Glucocorticoid-Induced Osteoporosis.
    N Engl J Med. 2018;379:2547-2556.
    PubMed    


    March 2018
  9. GOLLOGLY L, Norris S, Ford N
    Correcting the Record on a Fracture Risk Assessment Tool.
    N Engl J Med. 2018;378:867-868.
    PubMed    


    January 2018

  10. Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
    N Engl J Med. 2018;378:194-196.
    PubMed    


  11. TSOURDI E, Rachner TD, Hofbauer LC
    Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
    N Engl J Med. 2018;378:195.
    PubMed    


  12. LEWIS JR, Schousboe JT, Prince RL
    Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
    N Engl J Med. 2018;378:194-5.
    PubMed    


  13. SONG GG, Lee YH
    Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
    N Engl J Med. 2018;378:194.
    PubMed    


    October 2017
  14. ROSEN CJ
    Romosozumab - Promising or Practice Changing?
    N Engl J Med. 2017;377:1479-1480.
    PubMed    


    September 2017
  15. SAAG KG, Petersen J, Brandi ML, Karaplis AC, et al
    Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    N Engl J Med. 2017 Sep 11. doi: 10.1056/NEJMoa1708322.
    PubMed     Abstract available


    May 2017
  16. ROCA-AYATS N, Balcells S, Garcia-Giralt N, Falco-Mascaro M, et al
    GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates.
    N Engl J Med. 2017;376:1794-1795.
    PubMed    


    January 2017
  17. KALYAN SH
    Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:395-6.
    PubMed    


  18. BANHIDY NF, MacKinnon TS, Banhidy FP
    Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:395.
    PubMed    


  19. SHARMA R, Torka P
    Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:395.
    PubMed    


  20. KRANENBURG G, Bartstra JW, de Jong PA
    Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:396.
    PubMed    



  21. Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:396-7.
    PubMed    


    September 2016
  22. ROSEN CJ, Ingelfinger JR
    Building Better Bones with Biologics - A New Approach to Osteoporosis?
    N Engl J Med. 2016.
    PubMed    


  23. COSMAN F, Crittenden DB, Adachi JD, Binkley N, et al
    Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    N Engl J Med. 2016.
    PubMed     Abstract available


    May 2016

  24. Postmenopausal Osteoporosis.
    N Engl J Med. 2016;374:1797.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: